Albemarle CorpAnalysts cut Albemarle's quarterly and fiscal-year earnings estimates, and shares fell 14.3% over the past month.

Albemarle has drawn heightened investor attention after its shares returned -14.3% over the past month, compared with a -1.3% change for the Zacks S&P 500 composite and a 6.3% loss for the Zacks Chemical - Diversified industry. For the current quarter, the company is expected to post earnings of $2.55 per share, a change of +1442.1% from the year-ago quarter, though the Zacks Consensus Estimate has fallen 15.9% over the last 30 days. For the current fiscal year, the consensus earnings estimate of $11.39 points to a change of +1541.8% from the prior year and has declined 4.4% over the past month, while the next fiscal year's estimate of $11.07 indicates a -2.8% change and has slipped 3.9%. The consensus sales estimate of $1.52 billion for the current quarter points to a year-over-year change of +16.1%, with $6.1 billion and $6.35 billion expected for the current and next fiscal years. Albemarle reported revenues of $1.74 billion in the last reported quarter, up 31.1% year over year, with EPS of $3.75 versus $0.11 a year ago, and carries a Zacks Rank #3 (Hold) and a Zacks Value Style Score of B.
Albemarle CorpAnalysts cut Albemarle's quarterly and fiscal-year earnings estimates, and shares fell 14.3% over the past month.
China Nonferrous Mining Corp Ltd